drugset / Trial / NCT03967795

Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients

NCT03967795 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

The French intensive care societies (SRLF and SFAR), in agreement with the European and American societies for enteral and parenteral nutrition, recommend to quickly administer an artificial nutrition to patients admitted to ICU and for which it is expected that they will not be able to eat normally in the three days of admission. Enteral nutrition should be used in priority if the gut is functioning. However, intolerance to enteral nutrition, such as vomiting, regurgitation, increased residual gastric volume, or diarrhea, occurs in 40% of patients hospitalized in ICU receiving enteral nutrition. Intolerance to enteral nutrition leads to the risk of not receiving enough nutrition. Feeding intolerance also exposes to the risk of acute mesenteric ischemia, especially in the most severe patients under catecholamine for shock. Currently, it is not possible to predict intolerance to enteral nutrition in ICU patients. Thus, the diagnosis of intolerance is made a posteriori while enteral nutrition is in progress. Citrullinemia (normal concentration of 20 to 60 μmol / L), could be a good biomarker of the function of enterocytes involved in the absorption of food. The aim of this study is to evaluate the interest of citrullinemia to predict tolerance to enteral nutrition in ICU patients.

Timeline

Start
2019-11-28
Primary completion
2023-03-27
Completion
2023-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject N2-L-Alanyl-L-Glutamine Peptide 20 g Intravenous

Indications

No indication recorded.